Dyne Therapeutics Inc. has announced its financial results for the first quarter of 2025. The company reported a net loss of $115.4 million for the quarter ended March 31, 2025, compared to a net loss of $65.6 million for the same period in 2024. The R&D expenses for the quarter were $106.4 million, a significant increase from $44.5 million in the first quarter of 2024. General and administrative expenses decreased to $15.9 million from $24.6 million in the previous year. Dyne Therapeutics also highlighted recent business updates, including a Type C meeting with the FDA for DYNE-101 in DM1 held in May 2025. The company plans to provide a regulatory update following the receipt of meeting minutes. Furthermore, a Registrational Expansion Cohort of the ACHIEVE Trial of DYNE-101 in DM1 was initiated to support a potential submission for U.S. Accelerated Approval in the first half of 2026. Similarly, the Registrational Expansion Cohort of the DELIVER Trial of DYNE-251 in DMD is fully enrolled to support a potential submission for U.S. Accelerated Approval in early 2026. Dyne's cash, cash equivalents, and marketable securities totaled $677.5 million as of March 31, 2025. The company expects that this will be sufficient to fund its operations at least into the second half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.